Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542410 · ClinicalTrials.gov registry record · Phase 2
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02542410 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT02542410, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.
Interventions
- DRUG Cabergoline
- DRUG Norethindrone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542410
The ClinicalTrials.gov registry entry for NCT02542410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabergoline is the first listed.
NCT02542410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542410 about?
NCT02542410 is a clinical study titled "Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study". The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.
What is the current status of trial NCT02542410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02542410?
The interventions under investigation include: Cabergoline (DRUG), Norethindrone acetate (DRUG).
Who is sponsoring clinical trial NCT02542410?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.